Discovery of potential nicotinic acid receptor agonists from Chinese herbal medicines based on molecular simulation.
- Author:
Lu-Di JIANG
;
Yu-Su HE
;
Yan-Ling ZHANG
- Publication Type:Journal Article
- MeSH:
Drug Evaluation, Preclinical;
Drugs, Chinese Herbal;
chemistry;
Humans;
Models, Molecular;
Molecular Structure;
Nicotinic Acids;
chemistry;
Nicotinic Agonists;
chemistry;
Protein Binding;
Receptors, G-Protein-Coupled;
agonists;
chemistry;
Receptors, Nicotinic;
chemistry
- From:
China Journal of Chinese Materia Medica
2014;39(23):4653-4657
- CountryChina
- Language:Chinese
-
Abstract:
Nicotinic acid could increase high density lipoprotein and reduce serum total cholesterol, low density lipoprotein cholesterol and triglycerides in human bodies, thus is frequently applied in treating low high-density lipoprotein cholesterol and hypertriglyceridemia in clinic. However, according to the findings, nicotinic acid could also cause adverse effects, such as skin flush, beside its curative effects. In this study, bioisosterism, fragment-based search and Lipinski's Rule of Five were used to preliminarily screen out potential TCM ingredients that may have similar pharmacological effects with nicotinic acid from Traditional Chinese medicine database (TCMD). Afterwards, homology modeling and flexible docking were used to further screen out potential nicotinic acid receptor agonists. As a result, eleven candidate compounds were derived from eight commonly used traditional Chinese medicines. Specifically, all of the candidate compounds' interaction with nicotinic acid receptor was similar to nicotinic acid, and their docking scores were all higher than that of nicotinic acid, but their druggability remained to be further studied. Some of the eight source traditional Chinese medicines were used to lower lipid according to literature studies, implying that they may show effect through above means. In summary, this study provides basis and reference for extracting new nicotinic acid receptor agonists from traditional Chinese medicines and improving the medication status of hyperlipidemia.
